| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs | Sarah de Crescenzo | 05/28/20 | Seattle |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations | Sarah de Crescenzo | 05/27/20 | New York |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| AMAG Pharma Sells Off Women’s Health Product in Planned Divestment | Sarah de Crescenzo | 05/22/20 | Boston |
| Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes | Frank Vinluan | 05/21/20 | Boston |
| Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases | Frank Vinluan | 05/19/20 | New York |
| ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon | Frank Vinluan | 05/15/20 | New York |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq | Frank Vinluan | 05/15/20 | New York |
| Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System | Frank Vinluan | 05/14/20 | New York |
| Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline | Sarah de Crescenzo | 05/14/20 | New York |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study | Sarah de Crescenzo | 05/11/20 | National |
| Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug | Frank Vinluan | 05/08/20 | Indiana |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs | Frank Vinluan | 05/08/20 | National |
| PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug | Sarah de Crescenzo | 05/07/20 | New York |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M | Sarah de Crescenzo | 05/04/20 | New York |
| Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs | Frank Vinluan | 05/04/20 | Boston |
| Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine | Frank Vinluan | 05/01/20 | Europe |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans | Frank Vinluan | 04/27/20 | New York |
